EUVIMEDEUVIMED entdecken
Open Access

Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Megan Montoya iD, Sara A Collins, Pavlina Chuntova iD, Trishna S Patel, Takahide Nejo iD, Akane Yamamichi, Noriyuki Kasahara iD, Hideho Okada iD

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Megan Montoya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Glioblastoma, Tumor Microenvironment, Interferon Regulatory Factors, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could “reprogram” intratumoral MDSCs into antigen-presenting cells and thereby restore T-cell responses.

Methods

Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. The immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presentation by ex vivo T-cell-myeloid co-culture.

Results

Intratumoral injection of RRV-IRF8 in mice bearing intracerebral SB28 glioma significantly suppressed tumor growth and prolonged survival. RRV-IRF8 treated tumors exhibited significant enrichment of cDC1s and CD8+ T-cells. Additionally, myeloid cells derived from RRV-IRF8 tumors showed decreased expression of the immunosuppressive markers Arg1 and IDO1 and demonstrated reduced suppression of naïve T-cell proliferation in ex vivo co-culture, compared to controls. Furthermore, DCs from RRV-IRF8 tumors showed increased antigen presentation compared to those from control tumors. In vivo treatment with azidothymidine (AZT), a viral replication inhibitor, showed that IRF8 transduction in both tumor and non-tumor cells is necessary for survival benefit, associated with a reprogrammed, cDC1- and CD8 T-cell-enriched TIME.

Conclusions

Our results indicate that reprogramming of glioma-infiltrating myeloid cells by in vivo expression of IRF8 may reduce immunosuppression and enhance antigen presentation, achieving improved tumor control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor MicroenvironmentInterferon Regulatory FactorsBrain NeoplasmsAnimalsMiceAdaptive ImmunityMice, Inbred C57BLMyeloid-Derived Suppressor CellsDendritic CellsCellular ReprogrammingImmune ToleranceInterferon Regulatory Factor-8

Stichwörter der Autor:innen

IRF8MDSCRRV-mediated gene therapyglioblastomaimmunosuppression

Substanzen

Interferon Regulatory FactorsInterferon Regulatory Factor-8

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
  • Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
  • The Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.

ORCID-Profile: Megan Montoya, Pavlina Chuntova, Takahide Nejo, Noriyuki Kasahara, Hideho Okada

Förderung

  • NIGMS NIH HHS
  • NINDS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Montoya, M., Collins, S. A., Chuntova, P., Patel, T. S., Nejo, T., Yamamichi, A., Kasahara, N., & Okada, H. (2024). Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae149

Vancouver

Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, et al. Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae149

BibTeX
@article{Montoya2024,
  author = {Montoya, Megan and Collins, Sara A and Chuntova, Pavlina and Patel, Trishna S and Nejo, Takahide and Yamamichi, Akane and Kasahara, Noriyuki and Okada, Hideho},
  title = {Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae149}
}
Kostenlos starten →